CD274 and non-small cell lung carcinoma: Although the results of preliminary phase III clinical trials of anti‐PD‐1/PD‐L1 treatment for NSCLC have suggested that expression of PD‐L1 can predict the response to this type of treatment, expression of PD‐L1 is not considered to be a perfect biomarker.